WO2006104086A1 - 血栓症治療剤 - Google Patents
血栓症治療剤 Download PDFInfo
- Publication number
- WO2006104086A1 WO2006104086A1 PCT/JP2006/306125 JP2006306125W WO2006104086A1 WO 2006104086 A1 WO2006104086 A1 WO 2006104086A1 JP 2006306125 W JP2006306125 W JP 2006306125W WO 2006104086 A1 WO2006104086 A1 WO 2006104086A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aspirin
- thrombosis
- pitapastatin
- therapeutic agent
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the present invention relates to a thrombosis therapeutic agent, and more particularly to a thrombosis therapeutic agent that is effective against blood coagulation inhibition and thrombus dissolution!
- thrombosis In thrombosis, thrombus formation in arterial or venous blood vessels is caused by an increase in platelet aggregation ability, an increase in blood coagulation ability due to activation of blood coagulation factors, and a decrease in thrombolysis ability, alone or in combination. As a result, blood circulation failure occurs.
- the resulting ischemia causes a decrease in oxygen and nutrient supply in peripheral tissues including the brain, heart, and other organs, and is strongly associated with the onset of diseases that lead to fatal symptoms such as cerebral infarction and myocardial infarction. I am involved. Therefore, the treatment of thrombosis is considered important in the diseases in the above fields.
- Antiplatelet agents that suppress platelet aggregation such as aspirin, ticlovidin, eicosapentaenoic acid (EPA), dipyridamole, dilazep hydrochloride, and anticoagulants that suppress blood coagulation factors such as ⁇ rufaline, heparin, low molecular weight heparin, and argatroban Administration of these alone or in combination is central to treatment.
- Anti-platelet agents such as aspirin suppress the platelet aggregation ability, thereby reducing the blood coagulation progression field caused by platelet aggregation force S and suppressing the ability to form blood clots and blood clots at the site of vascular injury. .
- platelets since platelets also have the function of preventing bleeding from blood vessels, excessively suppressing this leads to a decrease in the physiological ability to prevent bleeding, which is sufficient for the treatment of thrombosis with antiplatelet agents. It is often difficult to secure the quantity.
- antiplatelet agents such as aspirin do not exhibit direct anticoagulant activity, it is often difficult to achieve sufficient antithrombotic activity with antiplatelet agents alone in patients with thrombosis.
- the aspirin dilemma caused by high-dose aspirin administration Are known. In other words, it can cause serious gastrointestinal disorders by suppressing the production of physiological gastrointestinal mucosa protective substances, and can induce blood circulation disorders by inhibiting the production of physiological vasodilatory substances.
- Known methods for increasing doses of aspirin are not recommended. From this aspect, it becomes difficult to administer a sufficient amount of aspirin necessary for the treatment of thrombosis.
- anticoagulants may also cause side effects such as bleeding when administered at a high dose, and it is often difficult to administer a sufficient amount of anticoagulant necessary for the treatment of embolism.
- an antiplatelet agent such as aspirin
- an anticoagulant an anticoagulant
- Patent Document 1 discloses an antithrombotic agent by the combined administration of an HMG-CoA reductase inhibitor and aspirin.
- HMG-CoA reductase inhibitor has a strong HMG-CoA reductase inhibitory action and is not positioned as a therapeutic agent for force thrombosis, which is known to be useful as a blood cholesterol lowering agent.
- there is no specific description of the effect of the combined administration and the extent to which it is unclear.
- Patent Documents 2 and 3 are one of HMG-CoA reductase inhibitors, and aspirin.
- Patent Document 1 Pamphlet of International Publication No. 98Z11896
- Patent Document 2 US Pat. No. 5,856,336
- Patent Document 3 JP-A-1-279866
- an object of the present invention is to provide a therapeutic agent for thrombosis that is effective for both blood coagulation inhibition and thrombolysis with few side effects.
- the present invention provides a therapeutic agent for thrombosis characterized by containing pitapastatins and aspirin.
- the present invention also provides use of pitapastatins and aspirin for the production of a therapeutic agent for thrombosis.
- the present invention provides a method for treating thrombosis characterized by co-administration of pitapastatins and aspirin.
- the therapeutic agent for thrombosis according to the present invention is remarkably superior to the combination of other HMG-CoA reductase inhibitors and aspirin due to both excellent anticoagulant action and thrombolysis enhancing action. It exhibits antithrombotic activity and is effective in the treatment of thrombosis associated with hypertension, vasospasm, arteriosclerosis, diabetes, surgery, blood stasis alone or in combination.
- the combined administration of pitapastatins and aspirin exhibits a stronger antithrombotic effect than the administration of aspirin alone, so that it is only possible to avoid the administration of high doses of aspirin with side effects and normal administration of aspirin. By reducing the dose, it is possible to reduce the side effects of aspirin itself.
- Pitapastatins used in the present invention include pitapastatin ((3R, 5S, 6E) 7— [2-cyclopropyl 4- (4-fluorophenol) 3-quinolyl] — 3, 5-dihydroxy 16 heptenoic acid): U.S. Pat. No. 5,856,336, JP-A-1-279866), its lactone ring-former and its salt, and hydrates of these with pharmaceutically acceptable solvents Things are also included.
- the salt include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as strength salt and magnesium salt; organic amine salt such as phenethylamine salt or ammonium salt. Of these, as pitanostatin, a salt of pitapastatin is preferred, and a calcium salt is particularly preferred.
- Aspirin in the present invention represents acetyl salicylic acid and can be easily obtained as a commercial product.
- the aspirin forms a salt with, for example, sodium, calcium, or aluminum!
- pitapastatins and aspirin are administered in combination.
- pitapastatins are present in guinea pigs as compared to the case where aspirin is administered alone. It has the effect of prolonging the clotting time (anticoagulant effect) and suppressing the formation of maximum blood clot (thrombolysis enhancing effect).
- the therapeutic agent for thrombosis of the present invention is effective for the treatment of thrombosis that develops on the basis of vascular disorders associated with diseases such as hypertension, vasospasm, arteriosclerosis, diabetes, external surgery, blood stasis alone or in combination. is there.
- the mode of use of pitapastatins and aspirin in the therapeutic agent for thrombosis of the present invention is not particularly limited, and each preparation may be administered separately or may be administered as a single preparation. Moreover, you may administer simultaneously and may administer separately at intervals. The frequency of administration of each component may be different.
- the weight ratio of pitapastatin and aspirin should be in the range of 1: 2.5 to 1: 300, and in the range of 1: 2.5 to 1: 150. Good.
- pitapastatins and aspirin can be mixed with pharmaceutically acceptable diluents, excipients, etc. into a single formulation, or both drugs can be formulated separately as a set (kit) Also good. When both drugs are formulated separately, both preparations need not be in the same dosage form.
- Examples of the administration form of the medicament of the present invention include oral administration using tablets, capsules, granules, powders, solutions, syrups and the like.
- the formulation is a pharmaceutically acceptable excipient, disintegrant, binder, lubricant, diluent, buffer, isotonic agent, preservative, lubricant, depending on the dosage form. It can be mixed with an agent, emulsifier, dispersant, stabilizer, solubilizer, etc. as appropriate, diluted or dissolved, and manufactured according to a conventional method.
- the doses of pitanostatin and aspirin are appropriately selected depending on the patient's weight, age, sex, symptoms, etc.
- the class is 1 to: L00 mg, preferably 1 to 50 mg, more preferably 1 to 20 mg.
- Aspirin is preferably administered to 10 to 300 mg, preferably 10 to 100 mg. The administration may be once a day, but may be divided into two or more times.
- Hartley male guinea pig (Japan SLC Co., Ltd.) A 6-week-old was tested. Throughout the experiment period, the light-dark cycle (bright period of room light: 7 am-7pm), raised in a breeding room maintained at a temperature of 23 people 3 ° C and a humidity of 55 people 15%, solid feed (RC4; Oriental Yeast Co., Ltd.) and tap water were allowed to drink freely.
- Pitapastatin calcium or aspirin was suspended in a 0.5% by mass aqueous solution of carboxymethylcellulose sodium (Iwai Chemicals Co., Ltd.) and the concentration was adjusted to 1 mgZmL to 10 mg / mL, respectively. Since pitapastatin calcium contains 9.43% by mass of water, it was corrected by weighing 1.1 mass times the dose. The suspension was stored refrigerated (4 ° C) in a light shielding bottle, and preparation was performed every 7 days.
- guinea pigs in the following 4 groups (6 patients in each group): control (no drug) group, pitavastatin calcium alone (3 mgZkg) group, aspirin alone (lOOmgZkg) group, and pitapastatin calcium (3 mgZkg) And aspirin (lOOmgZkg) Grouped into groups. Both drugs were orally administered once a day (4 pm) repeatedly for 14 days, and the control group was orally administered with 0.5 mL aqueous sodium carboxymethylcellulose solution lmLZkg. In each group, blood was collected after fasting for 18 hours from the final administration, and the whole blood clotting time (r + k value) and maximum clot formation ability (MA) were measured using a thromboelastograph (Helige).
- r + k value whole blood clotting time
- MA maximum clot formation ability
- atorvastatin calcium hydrate US Pat. Nos. 4681893 and 5273995, JP-A-3-58967
- atorvastatin calcium hydrate which is one of typical HMG-CoA reductase inhibitors, sympastatin ( U.S. Pat. No. 4444784) or pravastatin sodium (U.S. Pat. No. 4,346,227)
- whole blood clotting time r + k value
- MA maximum clot formation ability
- atorvastatin calcium is expressed as atorvastatin
- the whole blood clotting time r + The prolongation effect on (k value) was unacceptable.
- the maximum blood clot formation ability MA was also found to have no inhibitory effect by combined administration. That is, when atorvastatin calcium hydrate and aspirin were administered in combination, both the blood coagulation inhibitory action and the thrombolysis enhancing action were potently confirmed.
- Figure 1 shows the effect of prolonging the thrombolastograph whole blood clotting time (r + k value) (anticoagulant action) by the combined use of pitapastatin calcium (referred to as pitapastatin) and aspirin FIG.
- FIG. 2 is a graph showing the maximum clot formation ability (MA) inhibitory effect (thrombolysis enhancing action) by the combined administration of pitano-statin calcium (referred to as pitapastatin) and aspirin.
- MA maximum clot formation ability
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06730073A EP1864662A4 (en) | 2005-03-28 | 2006-03-27 | THERAPEUTIC AGENT AGAINST THROMBOSE |
JP2007510480A JP4839309B2 (ja) | 2005-03-28 | 2006-03-27 | 血栓症治療剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66539005P | 2005-03-28 | 2005-03-28 | |
US60/665,390 | 2005-03-28 | ||
US11/158,080 US7598233B2 (en) | 2005-03-28 | 2005-06-22 | Method for treating thrombosis |
US11/158,080 | 2005-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006104086A1 true WO2006104086A1 (ja) | 2006-10-05 |
Family
ID=37035987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/306125 WO2006104086A1 (ja) | 2005-03-28 | 2006-03-27 | 血栓症治療剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7598233B2 (ja) |
EP (1) | EP1864662A4 (ja) |
JP (1) | JP4839309B2 (ja) |
KR (1) | KR101261077B1 (ja) |
WO (1) | WO2006104086A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019520377A (ja) * | 2016-06-28 | 2019-07-18 | アサメディック アクティーゼルスカブAsamedic As | 二成分組成物 |
US11844806B2 (en) | 2017-12-22 | 2023-12-19 | Asamedic As | Compositions comprising acetylsalicylic acid and a phosphate salt |
US11850253B2 (en) | 2017-12-22 | 2023-12-26 | Asamedic As | Two component compositions |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1614429A4 (en) * | 2003-04-17 | 2007-05-02 | Kowa Co | LKLF / KLF2 GEN-EXPRESSIONSPROMOTER |
WO2011076401A1 (de) | 2009-12-23 | 2011-06-30 | Holger Schankin | Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen |
WO2013040507A1 (en) * | 2011-09-15 | 2013-03-21 | Omthera Pharmaceuticals, Inc. | Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy |
LV14963B (lv) * | 2013-06-28 | 2015-10-20 | Tetra, Sia | Endoteliālās disfunkcijas korektors |
US10183044B2 (en) * | 2015-05-15 | 2019-01-22 | P Tech, Llc | Systems and methods for thrombosis prevention |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001500875A (ja) * | 1996-09-18 | 2001-01-23 | メルク エンド カンパニー インコーポレーテッド | 心臓血管系疾患関連の危険性を減らす併用治療法 |
WO2003086466A1 (fr) * | 2002-04-12 | 2003-10-23 | Kowa Company, Ltd. | Nouveaux promoteurs de l'expression de la thrombomoduline |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US6235706B1 (en) * | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6465477B1 (en) * | 1997-08-18 | 2002-10-15 | Kowa Company, Ltd. | Stable pharmaceutical composition |
AU2002306868A1 (en) * | 2001-03-28 | 2002-10-15 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
KR20040026705A (ko) * | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
MY131170A (en) * | 2002-03-28 | 2007-07-31 | Nissan Chemical Ind Ltd | Therapeutic agent for glomerular disease |
ITMI20021012A1 (it) * | 2002-05-13 | 2003-11-13 | Giovanni Scaramuzzino | Combinazione di un inibitore dell'enzima hmg-coa reduttasi e di un estere nitrato |
-
2005
- 2005-06-22 US US11/158,080 patent/US7598233B2/en not_active Expired - Fee Related
-
2006
- 2006-03-27 WO PCT/JP2006/306125 patent/WO2006104086A1/ja active Application Filing
- 2006-03-27 KR KR1020077021697A patent/KR101261077B1/ko not_active IP Right Cessation
- 2006-03-27 JP JP2007510480A patent/JP4839309B2/ja not_active Expired - Fee Related
- 2006-03-27 EP EP06730073A patent/EP1864662A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001500875A (ja) * | 1996-09-18 | 2001-01-23 | メルク エンド カンパニー インコーポレーテッド | 心臓血管系疾患関連の危険性を減らす併用治療法 |
WO2003086466A1 (fr) * | 2002-04-12 | 2003-10-23 | Kowa Company, Ltd. | Nouveaux promoteurs de l'expression de la thrombomoduline |
Non-Patent Citations (1)
Title |
---|
See also references of EP1864662A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019520377A (ja) * | 2016-06-28 | 2019-07-18 | アサメディック アクティーゼルスカブAsamedic As | 二成分組成物 |
US11918554B2 (en) | 2016-06-28 | 2024-03-05 | Asamedic As | Two-component composition |
US11844806B2 (en) | 2017-12-22 | 2023-12-19 | Asamedic As | Compositions comprising acetylsalicylic acid and a phosphate salt |
US11850253B2 (en) | 2017-12-22 | 2023-12-26 | Asamedic As | Two component compositions |
Also Published As
Publication number | Publication date |
---|---|
JP4839309B2 (ja) | 2011-12-21 |
EP1864662A4 (en) | 2010-06-23 |
KR20080002770A (ko) | 2008-01-04 |
US7598233B2 (en) | 2009-10-06 |
JPWO2006104086A1 (ja) | 2008-09-04 |
KR101261077B1 (ko) | 2013-05-06 |
US20060217352A1 (en) | 2006-09-28 |
EP1864662A1 (en) | 2007-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4839309B2 (ja) | 血栓症治療剤 | |
CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
JP2009513713A5 (ja) | ||
JP2005526130A (ja) | Aceインヒビター、カルシウムチャネルブロッカーおよび利尿剤の組合せ | |
WO2006025378A1 (ja) | 高脂血症治療剤 | |
RU2010129825A (ru) | Материалы и способы для лечения патологической пролиферации глазных сосудов | |
EP3035934A2 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
JP2013529654A (ja) | レボカルニチン及びドベシレートを含む医薬組成物 | |
JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
TW200306853A (en) | Therapeutic agent for glomerular disease | |
JP2010532348A5 (ja) | ||
JP2007518768A (ja) | 有機化合物の組み合わせ物 | |
JP2012514652A (ja) | 心血管疾患および脂質異常症を治療するための分泌ホスホリパーゼa2(spla2)インヒビターとナイアシン薬との組成物および方法 | |
JP2005120098A (ja) | 虚血性障害の処置用医薬品の製造のためのメラガトランの使用 | |
WO2006011495A1 (ja) | 高コレステロール血症及び/又は高トリグリセリド血症治療剤 | |
JP5775096B2 (ja) | インフルエンザの治療剤または予防剤 | |
JP4855073B2 (ja) | 併用医薬 | |
WO2008015763A1 (fr) | Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire | |
US9597322B2 (en) | Otamixaban for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting | |
WO2003047591A1 (en) | Remedies for primary pulmonary hypertension | |
WO2022122010A1 (zh) | Jak抑制剂在肾脏疾病中的应用 | |
WO2020184703A1 (ja) | 大動脈瘤の治療用医薬組成物 | |
JP2022152709A (ja) | マラリア予防治療薬 | |
WO2007013845A1 (en) | Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution | |
CA2720278A1 (en) | Agent for preventing and/or treating vascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680009013.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007510480 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2006730073 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006730073 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077021697 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006730073 Country of ref document: EP |